|
1
|
Duffy MJ, McGowan PM and Gallagher WM:
Cancer invasion and metastasis: changing views. J Pathol.
214:283–293. 2008. View Article : Google Scholar
|
|
2
|
Carlin BI and Andriole GL: The natural
history, skeletal complications, and management of bone metastases
in patients with prostate carcinoma. Cancer. 88(Suppl 12):
S2989–S2994. 2000. View Article : Google Scholar
|
|
3
|
Papachristou DJ, Basdra EK and
Papavassiliou AG: Bone metastases: molecular mechanisms and novel
therapeutic interventions. Med Res Rev. 32:611–636. 2012.
View Article : Google Scholar
|
|
4
|
Höckel M and Vaupel P: Biological
consequences of tumor hypoxia. Semin Oncol. 28(Suppl 8): S36–S41.
2001. View Article : Google Scholar
|
|
5
|
Greco O, Marples B, Joiner MC and Scott
SD: How to overcome (and exploit) tumor hypoxia for targeted gene
therapy. J Cell Physiol. 197:312–325. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brizel DM, Scully SP, Harrelson JM, et al:
Tumor oxygenation predicts for the likelihood of distant metastases
in human soft tissue sarcoma. Cancer Res. 56:941–943.
1996.PubMed/NCBI
|
|
7
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang GL and Semenza GL: Purification and
characterization of hypoxia-inducible factor 1. J Biol Chem.
270:1230–1237. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhong H, De Marzo AM, Laughner E, et al:
Overexpression of hypoxia-inducible factor 1α in common human
cancers and their metastases. Cancer Res. 59:5830–5835.
1999.PubMed/NCBI
|
|
10
|
Blagosklonny MV: Hypoxia-inducible factor:
Achilles’ heel of antiangiogenic cancer therapy (Review). Int J
Oncol. 19:257–262. 2001.PubMed/NCBI
|
|
11
|
Maxwell PH, Dachs GU, Gleadle JM, et al:
Hypoxia-inducible factor-1 modulates gene expression in solid
tumors and influences both angiogenesis and tumor growth. Proc Natl
Acad Sci USA. 94:8104–8109. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chaffer CL and Weinberg RA: A perspective
on cancer cell metastasis. Science. 331:1559–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Monteiro J and Fodde R: Cancer stemness
and metastasis: therapeutic consequences and perspectives. Eur J
Cancer. 46:1198–1203. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marignol L, Coffey M, Lawler M and
Hollywood D: Hypoxia in prostate cancer: a powerful shield against
tumour destruction. Cancer Treat Rev. 34:313–327. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharifi N, Kawasaki BT, Hurt EM and Farrar
WL: Stem cells in prostate cancer: resolving the castrate-resistant
conundrum and implications for hormonal therapy. Cancer Biol Ther.
5:901–906. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pfeiffer MJ and Schalken JA: Stem cell
characteristics in prostate cancer cell lines. Eur Urol.
57:246–254. 2010. View Article : Google Scholar
|
|
17
|
Ma Y, Liang D, Liu J, et al: Prostate
cancer cell lines under hypoxia exhibit greater stem-like
properties. PLoS One. 6:e291702011. View Article : Google Scholar
|
|
18
|
Marie-Egyptienne DT, Lohse I and Hill RP:
Cancer stem cells, the epithelial to mesenchymal transition (EMT)
and radioresistance: potential role of hypoxia. Cancer Lett.
341:63–72. 2013. View Article : Google Scholar
|
|
19
|
Higgins DF, Kimura K, Bernhardt WM, et al:
Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of
epithelial-to-mesenchymal transition. J Clin Invest. 117:3810–3820.
2007.PubMed/NCBI
|
|
20
|
Thiery JP: Epithelial-mesenchymal
transitions in development and pathologies. Curr Opin Cell Biol.
15:740–746. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nauseef JT and Henry MD:
Epithelial-to-mesenchymal transition in prostate cancer: paradigm
or puzzle? Nat Rev Urol. 8:428–439. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sethi S, Macoska J, Chen W and Sarkar FH:
Molecular signature of epithelial-mesenchymal transition (EMT) in
human prostate cancer bone metastasis. Am J Transl Res. 3:90–99.
2010.PubMed/NCBI
|
|
24
|
Liu YB, Gao X, Deeb D, Arbab AS and Gautam
SC: Pristimerin induces apoptosis in prostate cancer cells by
down-regulating Bcl-2 through ROS-dependent ubiquitin-proteasomal
degradation pathway. J Carcinog Mutagen. (Suppl 6): 0052013.
|
|
25
|
Peng X, Guo W, Liu T, et al:
Identification of miRs-143 and -145 that is associated with bone
metastasis of prostate cancer and involved in the regulation of
EMT. PLoS One. 6:e203412011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Huang S, Guo W, Tang Y, Ren D, Zou X and
Peng X: miR-143 and miR-145 inhibit stem cell characteristics of
PC-3 prostate cancer cells. Oncol Rep. 28:1831–1837.
2012.PubMed/NCBI
|
|
27
|
Liao D, Corle C, Seagroves TN and Johnson
RS: Hypoxia-inducible factor-1α is a key regulator of metastasis in
a transgenic model of cancer initiation and progression. Cancer
Res. 67:563–572. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Visvader JE and Lindeman GJ: Cancer stem
cells in solid tumours: accumulating evidence and unresolved
questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bisson I and Prowse DM: WNT signaling
regulates self-renewal and differentiation of prostate cancer cells
with stem cell characteristics. Cell Res. 19:683–697. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Warfel NA and El-Deiry WS: HIF-1 HIF-1
signaling in drug resistance to chemotherapy. Curr Med Chem.
21:3021–3028. 2014. View Article : Google Scholar
|
|
31
|
Hayashida T, Jinno H, Kitagawa Y and
Kitajima M: Cooperation of cancer stem cell properties and
epithelial-mesenchymal transition in the establishment of breast
cancer metastasis. J Oncol. 2011:5914272011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Duggal R, Minev B, Geissinger U, et al:
Biotherapeutic approaches to target cancer stem cells. J Stem
Cells. 8:135–149. 2013.
|
|
33
|
Xu J, Wang R, Xie ZH, et al: Prostate
cancer metastasis: role of the host microenvironment in promoting
epithelial to mesenchymal transition and increased bone and adrenal
gland metastasis. Prostate. 66:1664–1673. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Whitbread AK, Veveris-Lowe TL, Lawrence
MG, Nicol DL and Clements JA: The role of kallikrein-related
peptidases in prostate cancer: potential involvement in an
epithelial to mesenchymal transition. Biol Chem. 387:707–714. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kasper S and Cookson MS: Mechanisms
leading to the development of hormone-resistant prostate cancer.
Urol Clin North Am. 33:201–210. vii2006. View Article : Google Scholar : PubMed/NCBI
|
